Table 3.
Effects of HFD and L. laricina administration on organ weights at sacrifice.
| Prevention protocol | Treatment protocol | |||||
|---|---|---|---|---|---|---|
| DIO | L. laricina | L. laricina | DIO | L. laricina | L. laricina | |
| 125 mg/kg | 250 mg/kg | 125 mg/kg | 250 mg/kg | |||
| Retroperitoneal fat pad (g) | 1.34 ± 0.05 | 1.26 ± 0.04 | 1.14 ± 0.05* | 1.51 ± 0.08 | 1.35 ± 0.24 | 1.44 ± 0.04 |
| Epididymal fat pad (g) | 2.40 ± 1.00 | 2.56 ± 0.08 | 2.56 ± 0.07 | 1.21 ± 0.03 | 1.32 ± 0.18 | 1.85 ± 0.12* |
| Brown fat pad (g) | 0.30 ± 0.03 | 0.33 ± 0.01 | 0.28 ± 0.02 | 0.44 ± 0.01 | 0.37 ± 0.06 | 0.42 ± 0.02 |
| Liver weight (g) | 1.77 ± 0.09 | 1.85 ± 0.05 | 1.80 ± 0.07 | 2.62 ± 0.15 | 2.44 ± 0.38 | 2.57 ± 0.12 |
| Liver index | 410 ± 2 | 429 ± 1 | 437 ± 1 | 551 ± 3 | 539 ± 5 | 555 ± 2 |
Measurements were obtained after 8 weeks (prevention) or 16 weeks (treatment) of administration with either HFD (DIO) or L. laricina at 125 or 250 mg/kg, which was incorporated in the HFD for 8 weeks in the prevention protocol and for the last 8 of 16 weeks in the treatment protocol. The liver index corresponds to liver weight (mg)/body weight (mg). All values represent the mean ± SEM (prevention protocol DIO = 11; L. laricina 125 = 13; L. laricina 250 = 13, and for the treatment protocol DIO = 7; L. laricina 125 = 5; L. laricina 250 = 8). ∗denotes that treated groups are significantly different as compared to DIO (one-way ANOVA; post hoc analysis Holm-Sidak or Bonferroni-Dunn test; P < 0.05).